What are the chemotherapy drugs used in chemotherapy for nerve tumors? Chemotherapy drugs for nerve tumor chemotherapy are important for patients. No matter what kind of disease it is, once it occurs, it should be treated in time. For this aspect of chemotherapy for nerve tumor, the following will be introduced by our experts. Neurological tumor chemotherapy drugs Nitrosoureas: Before temozolomide entered clinical treatment, nitrosoureas were the main therapeutic drugs for malignant gliomas due to their ability to better cross the blood-brain barrier. For example, a clinical study co-organized by RTOG and ECOG found that the efficacy of simultaneous radiotherapy with BCNU was significantly better than that of radiotherapy alone in the 40.years age group. Further analysis of the results showed that adjuvant chemotherapy with a nitrosourea-containing regimen was able to increase 1-year survival by 10. 1 percent and 2-year survival by 8.6 percent. An analysis of more than 3,000 patients with malignant gliomas also showed that postoperative radiotherapy combined with postoperative chemotherapy increased the 1-year survival rate from 40% to 46% and prolonged median life expectancy by 2 months compared with postoperative radiotherapy alone. Temozolomide: is a newly developed alkylating agent analog that is converted in vivo to MflC. who has a short half-life in vivo and can cause DNA methylation and DNA breaks. Early studies found that temozolomide alone was 21% effective in the treatment of recurrent malignant gliomas, much higher than methylbenzene (8%), and had a progression-free survival time of up to six months.The EORTC and the NCIC subsequently conducted a phase III clinical study of temozolomide in combination with radiotherapy, which randomized patients with well-defined diagnoses of glioblastoma multiforme to either a radiotherapy-only group or temozolomide-combined-radiotherapy group . The treatment regimen of the combination therapy group included simultaneous radiotherapy with temozolomide 75 mg/ (II12.d); adjuvant chemotherapy was given for a 6-month period after the completion of simultaneous radiotherapy with temozolomide 150 to 200 mg/m 2, dl to 5, Q28d. Compared with the radiotherapy alone group, temo-combined radiotherapy prolonged the median survival of the patients from 12. 1 months to 14. 6 months, and the overall survival rate was increased from 10. 4% to 26. 5%. to 26.5%. Therefore, radiotherapy combined with temozolomide treatment has now become the standard of care for glioblastoma multiforme. Further studies have found that the level of expression of the MGMT (6-methylguanine methyltransferase) protein determines which malignant gliomas are effective for temozolomide, and that patients in the temozolomide treatment group with a methylated MGMT promoter had a significant increase in efficacy, whereas temozolomide treatment was mostly ineffective in patients without a methylated palladium of the MGMT promoter. Common therapeutic adverse effects of temozolomide include nausea, vomiting, decreased appetite, malaise, and headache, and bone marrow toxicity is mostly mild. Other drugs: In addition to the drugs listed above, other drugs used in chemotherapy for CNS malignancies include methylbenzylhydrazine, irinotecan, and platinum-based regimens. These drugs are mostly used for second-line treatment of malignant gliomas.